Inhibrx Biosciences (INBX) Operating Leases: 2023-2025
Historic Operating Leases for Inhibrx Biosciences (INBX) over the last 2 years, with Sep 2025 value amounting to $7.0 million.
- Inhibrx Biosciences' Operating Leases rose 280.82% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year increase of 280.82%. This contributed to the annual value of $8.0 million for FY2024, which is 153.64% up from last year.
- According to the latest figures from Q3 2025, Inhibrx Biosciences' Operating Leases is $7.0 million, which was down 6.95% from $7.5 million recorded in Q2 2025.
- In the past 5 years, Inhibrx Biosciences' Operating Leases registered a high of $8.0 million during Q4 2024, and its lowest value of $1.8 million during Q3 2024.
- Moreover, its 3-year median value for Operating Leases was $7.0 million (2025), whereas its average is $5.4 million.
- Data for Inhibrx Biosciences' Operating Leases shows a peak YoY surged of 280.82% (in 2025) over the last 5 years.
- Inhibrx Biosciences' Operating Leases (Quarterly) stood at $3.2 million in 2023, then spiked by 153.64% to $8.0 million in 2024, then soared by 280.82% to $7.0 million in 2025.
- Its Operating Leases was $7.0 million in Q3 2025, compared to $7.5 million in Q2 2025 and $7.9 million in Q1 2025.